ReviewFrontiers in pharmacology2020
Hydroxychloroquine in COVID-19 Patients: Pros and Cons.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- CORonavirus-19 mild to moderate pneumonia Management with blood Ozonization in patients with Respiratory failure (CORMOR) multicentric prospective randomized clinical trial.International immunopharmacology · 2021Trial
- Trial
- The presumable combined effects of hydroxychloroquine and its metabolites on the blood lipids and glucose in the treatment of rheumatoid arthritis.Inflammopharmacology · 2025Article
- Phenotypic switch of vascular smooth muscle cells in COVID-19: Role of cholesterol, calcium, and phosphate.Journal of cellular physiology · 2024Review
- Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies.European journal of clinical pharmacology · 2023Review
- Long-Term Symptoms after Mild Coronavirus Disease in Healthy Healthcare Professionals: A 12-Month Prospective Cohort Study.International journal of environmental research and public health · 2023Article
- Review
- Cell and Animal Models for SARS-CoV-2 Research.Viruses · 2022Review
- Quinine Esters with 1,2-Azole, Pyridine and Adamantane Fragments.Molecules (Basel, Switzerland) · 2022Article
- Friend or Foe? Implication of the autophagy-lysosome pathway in SARS-CoV-2 infection and COVID-19.International journal of biological sciences · 2022Review
- Aspirin in COVID-19: Pros and Cons.Frontiers in pharmacology · 2022Review
- The effect ofFrontiers in pharmacology · 2022Article
- COVID-19: potential therapeutics for pediatric patients.Pharmacological reports : PR · 2021Review
- Neurological complications of COVID-19: from pathophysiology to rehabilitation. An overview.Acta bio-medica : Atenei Parmensis · 2021Article
- COVID-19-Associated Cardiovascular Complications.Diseases (Basel, Switzerland) · 2021Review
- Cardiac Manifestations in COVID-19 Patients: A Focus on the Pediatric Population.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2021Review
- Why Haven't We Found an Effective Treatment for COVID-19?Frontiers in immunology · 2021Review
- Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2021Review
- Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate.Travel medicine and infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pandemic of COVID-19, caused by SARS-CoV-2, has recently overwhelmed medical centers and paralyzed economies. The unparalleled public distress caused by this pandemic mandated an urgent quest for an effective approach to manage or treat this disease. Due to their well-established anti-infectious and anti-inflammatory properties, quinine derivatives have been sought as potential therapies for COVID-19. Indeed, these molecules were originally employed in the treatment and prophylaxis of malaria, and later in the management of various autoimmune rheumatic and dermatologic diseases. Initially, some promising results for the use of hydroxychloroquine (HCQ) in treating COVID-19 patients were reported by a few
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.